Therapeutic Treatment Options for In-Transit Metastases from Melanoma

In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and t...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-09, Vol.16 (17), p.3065
Main Authors: Russano, Francesco, Rastrelli, Marco, Dall'Olmo, Luigi, Del Fiore, Paolo, Gianesini, Carlomaria, Vecchiato, Antonella, Mazza, Marcodomenico, Tropea, Saveria, Mocellin, Simone
Format: Article
Language:English
Subjects:
Cancer
Chemotherapy
Disease control
Immune checkpoint inhibitors
Immune system
Immunotherapy
Lymphatic system
Medical prognosis
Melanoma
Metastases
Metastasis
Mutation
Patients
Quality of life
Surgery
Survival
Tomography
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM. Methods include a comprehensive review of clinical studies examining the impact of treatments like immune checkpoint inhibitors, targeted therapies, Isolated Limb Perfusion, and electrochemotherapy. The results indicate that combining systemic therapies with locoregional treatments enhances both local disease control and overall survival rates. The introduction of modern immunotherapies has not diminished the effectiveness of locoregional therapies but rather improved patient outcomes when used in conjunction. The conclusions emphasize that a multidisciplinary approach integrating systemic and locoregional therapies offers a promising strategy for optimizing the management of ITM in melanoma patients. This integrated treatment model not only improves survival rates but also enhances the quality of life for patients, suggesting a shift in standard care practices toward more comprehensive therapeutic regimens.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16173065